You are leaving this site You are about to leave www.grantformultiplesclerosisinnovation.org/. The content of the site you are about to visit is not controlled by www.grantformultiplesclerosisinnovation.org/.
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Rapid in vivo myelin and neurite density imaging: new promising quantitative and tissue-specific biomarkers for predicting disease progression and treatment response
The treatment of MS has been revolutionized in the past two decades; however, current treatments have mainly focused on modifying inflammatory disease activity. New emerging MS therapies show promise in enhancing remyelination, which is likely to be protective for axons and preventative of long-term disability. Studying the impact on demyelination and remyelination dynamics, and axonal integrity in vivo, requires robust and clinically feasible methods in order to monitor these physiological processes.
Dr Granberg hypothesizes that application of a combination of two new MRI techniques (REMyDI and NODDI), which provide improved microstructural characterization of MS pathology in vivo, can be applied to better detect and understand disease heterogeneity at onset. The validation of novel quantitative imaging outcomes will be beneficial for early-stage clinical trials of novel therapeutic drugs aimed at enhancing remyelination, as existing standard imaging techniques have lower sensitivity in determining changes over short timespans in progressive forms of MS.
Content provided by the researcher.